GFL Environmental (NYSE:GFL) 주식

GFL Environmental

GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.

News

Movers

COHR

COIN

CRWD

ESTC

GWRE

ILMN

NVDA

PLTR

RDDT

SAIA

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 가이드와이어 소프트웨어(NYSE:GWRE)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 상향 조정했다. 

Arm과 보잉은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 1일-6월 7일)

GFL Environmental Inc. Subordinate voting shares, no par value

GFL Environmental Inc

GENFLAT HOLDINGS INC. by GenFlat Holdings, Inc.

GenFlat Holdings Inc

VictoryShares Free Cash Flow Growth ETF

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and maintains $9 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Kohl's, Maintains $9 Price Target

WIIM

ULTA

Ulta shares are trading higher after the company reported better-than-expected Q1 financial results and raised guidance.

REGN

Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study didd not.

Telsey Advisory Group analyst Dana Telsey maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Market Perform and maintains $12 price target.

Telsey Advisory Group Maintains Market Perform on American Eagle Outfitters, Maintains $12 Price Target

Gap shares are trading lower after the company reported Q1 financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.

SCNI

Scinai Immunotherapeutics Reports Q1 Revenues Of $586,000; Exits Quarter With Cash & Equivalents Worth $1.01M

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), announced today that the Company and Dr. Raza Bokhari, Company's former Executive Chairman and Chief Executive Officer (CEO), have reached a global settlement agreement (the "agreement") to settle all and any disputes originating out of the proxy contest originally commencing January 2021. Mr. Zeeshan Saeed, Co-Chairman &amp; CEO, and Mr. Anthony Durkacz, Co-Chairman of the Company, also signed the agreement in their personal capacity.
The agreement brings to a complete and final closure all outstanding issues and prevents any future litigation in various courts in Canada and the United States. The payment of $2,350,000 USD from Dr. Bokhari to Quantum BioPharma Ltd. (Formerly FSD Pharma Inc.) satisfies all outstanding monetary claims by the Company, Zeeshan Saeed, Anthony Durkacz and other current or former employees, officers, Directors, affiliates or agents of the Company as well as any and all legal and monetary claims by Dr. Bokhari. The $2,350,000 USD is a non-dilutive injection of cash into Quantum BioPharma.
In the agreement, Dr. Raza Bokhari, Quantum BioPharma Ltd, Zeeshan Saeed and Anthony Durkacz did not admit to any wrongdoing. All parties agreed that at all times they were acting in the best interest of the corporation and the shareholders.

Legal

CSE:QNTM

QNTM

Quantum BioPharma Ends Legal Fight With Former CEO, Receives $2.35M Settlement

<a href="https://www.bloomberg.com/news/articles/2025-05-30/china-preps-70-billion-in-new-capital-to-supercharge-investment" title="https://www.bloomberg.com/news/articles/2025-05-30/china-preps-70-billion-in-new-capital-to-supercharge-investment">https://www.bloomberg.com/news/articles/2025-05-30/china-preps-70-billion-in-new-capital-to-supercharge-investment</a>

Macro Economic Events

Global

Economics

Bloomberg: China Plans To Allocate $70B Of Capital That Could Be Leveraged Up To Fast Track New Infrastructure Projects

Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.10) by 910 percent. This is a 27.85 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $45.75 million which missed the analyst consensus estimate of $49.92 million by 8.36 percent. This is a 15.29 percent decrease over sales of $54.00 million the same period last year.

Earnings

Earnings Misses

Canopy Growth Q4 EPS $(1.01) Misses $(0.10) Estimate, Sales $45.75M Miss $49.92M Estimate

Ascendiant Capital analyst Edward Woo maintains Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) with a Buy and raises the price target from $60 to $62.

VERB

Ascendiant Capital Maintains Buy on Verb Technology Co, Raises Price Target to $62

Laboratory Corporation Of America Holdings

Labcorp Expands Oncology Portfolio With New Tests For Solid And Blood Cancers; Reveals Expansion Of Capabilities To OmniSeq INSIGHT

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
&nbsp;
The CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
Updated results from the pilot phase indicate that four of eleven patients remained progression free after more than one year. Two patients underwent definitive treatment for mPDAC: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response. An analysis of pre- and on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination. In addition, patients achieving a partial response were found to have higher pre-treatment proportions of CXCL12-producing cancer associated fibroblasts, a potential marker of response.

BLRX

BioLineRx Reports Long-Term Tumor Control in Some Patients From New Pancreatic Cancer Combo Trial

Modine To Acquire L.B. White, Total Consideration Based On Enterprise Value Of $112M; L.B. White Expects To Report Revenue Of $73.5M For 2025 Fiscal Year Ending May 31

BRKR

Bruker Unveils timsMetabo Mass Spectrometer With Advanced TIMS 'MoRE' Scan-Mode

Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).
Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors.
"With the first participant now successfully enrolled, commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy."
"Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate," said James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and&nbsp;Allied Health&nbsp;at the&nbsp;University of North Carolina School of Medicine. "Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study."
The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.

RNAC

Cartesian Begins Phase 3 Trial of New Cell Therapy for Myasthenia Gravis Without Chemo

Needham analyst Quinn Bolton maintains Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Buy and lowers the price target from $110 to $90.

AMBA

Needham Maintains Buy on Ambarella, Lowers Price Target to $90

Biotech

Health Care

General

BCRX

Biocryst Pharmaceuticals Announced New Data Which Highlights The Reduction In The Percentage Of Days With Hereditary Angioedema (HAE) Symptoms Among Young Children Initiating Berotralstat In The Apex-P Trial, And The Broad Safety And Efficacy Outcomes Observed Across All Age Groups Of Patients Taking Orladeyo To Prevent HAE Attacks

Management

TLSI

TriSalus Life Sciences  Appoints David Patience As CFO, Effective Jul. 1

PLBY Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) (the "Company" or "PLBY Group"), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today announced that the Company will be included in the Russell Microcap&#xAE; Index at the conclusion of the 2025 Russell U.S. Indexes annual reconstitution, and will be in effect as of the opening of the U.S. stock market on June 30, 2025.

PLBY

PLBY Group To Be Included In Russell Microcap Index At Conclusion Of 2025 Russell U.S. Indexes Annual Reconstitution

Commodities

Press Releases

GFL Environmental Inc. Obtains Exemptive Relief from Issuer Bid Requirements

Offerings

GFL Environmental Inc. Announces Secondary Offering of 15,739,769 Subordinate Voting Shares by Selling Shareholders

GFL Environmental Inc. Announces Direct Share Buyback of 17,050,298 Subordinate Voting Shares from BC Partners and Intention to Repurchase up to 7,056,027 Subordinate Voting Shares in Secondary Offering

GFL Environmental Inc. Announces Upsize and Pricing of Secondary Offering by Selling Shareholders

GFL Environmental Inc. Announces Closing of Secondary Offering by Selling Shareholders

GFL Environmental Inc. Sets Date for Q1 2025 Earnings Release

Dividends

GFL Environmental Inc. Announces 10% Increase to Quarterly Dividend

GFL Environmental Inc. Resumes Share Repurchase Program

GFL Environmental Reports First Quarter 2025 Results

GFL Environmental Inc. Announces Results from Annual General Meeting of Shareholders

Comments

GFL Environmental

뉴스

파트너 / 기고자

벤징가 글로벌